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Background: Endocrine disruptors (EDs) are defined by the World Health Organization (WHO)
as exogenous compounds or mixtures that alter function(s) of the endocrine system and consequently cause adverse effects in an intact organism, or its progeny, or (sub)populations. European
regulations on pesticides, biocides, cosmetics, and industrial chemicals require the European
Commission to establish scientific criteria to define EDs.
Objectives: We address the scientific relevance of four options for the identification of EDs
proposed by the European Commission.
Discussion: Option 1, which does not define EDs and leads to using interim criteria unrelated to
the WHO definition of EDs, is not relevant. Options 2 and 3 rely on the WHO definition of EDs,
which is widely accepted by the scientific community, with option 3 introducing additional categories based on the strength of evidence (suspected EDs and endocrine-active substances). Option 4
adds potency to the WHO definition, as a decision criterion. We argue that potency is dependent
on the adverse effect considered and is scientifically ambiguous, and note that potency is not used
as a criterion to define other particularly hazardous substances such as carcinogens and reproductive
toxicants. The use of potency requires a context that goes beyond hazard identification and corresponds to risk characterization, in which potency (or, more relevantly, the dose–response function)
is combined with exposure levels.
Conclusions: There is scientific agreement regarding the adequacy of the WHO definition of
EDs. The potency concept is not relevant to the identification of particularly serious hazards such
as EDs. As is common practice for carcinogens, mutagens, and reproductive toxicants, a multi-level
classification of ED based on the WHO definition, and not considering potency, would be relevant
(corresponding to option 3 proposed by the European Commission).
Citation: Slama R, Bourguignon JP, Demeneix B, Ivell R, Panzica G, Kortenkamp A, Zoeller RT.
2016. Scientific issues relevant to setting regulatory criteria to identify endocrine disrupting
substances in the European Union. Environ Health Perspect 124:1497–1503; http://dx.doi.
org/10.1289/EHP217

Introduction
The regulation of chemicals identifies specific
classes of health hazards such as carcinogens,
mutagens, and reprotoxicants. Endocrine
disruptors (EDs) are a newer type of hazard
identified by research. The World Health
Organization (WHO) defined an ED as “an
exogenous substance or mixture that alters
the function(s) of the endocrine system and
consequently causes adverse effects in an
intact organism, or its progeny, or (sub)populations” (WHO/IPCS 2002). Following the
first scientific reference to EDs (Colborn et al.
1993), a large body of research has considerably improved our understanding of their
effects in wildlife and humans (e.g., Bergman
et al. 2013; Braun et al. 2011; Delfosse et al.
2014; Frye et al. 2012; Heindel et al. 2015;
Kortenkamp et al. 2011; Shelton et al. 2014;
Warner et al. 2014; Woodruff et al. 2011).
In 1999, the European Union (EU)
became the first major economy to develop a
strategy for the regulation of EDs (European
Environmental Health Perspectives •

volume

Commission 1999). Subsequently, EDs have
been addressed in at least four acts of EU
law: the water framework directive (European
Parliament 2000), REACH (the European
Regulation on Registration, Evaluation,
Authorisation and Restriction of Chemicals)
(European Parliament 2006), the Plant
Protection Products Regulation (PPPR)
(European Parliament 2009a), the Cosmetics
Regulation (European Parliament 2009b),
as well as the Biocidal Products Regulation
(BPR) (European Parliament 2012). The
two latter regulations required the European
Commission to establish scientific criteria to
identify substances with endocrine-disrupting
properties before December 2013.
The PPPR and the BPR specify that
substances with ED properties used as pesticides or biocides will not receive approval
for their use, with certain exceptions (e.g.,
if exposure is negligible, for the PPPR).
Similar provisions exist for carcinogens,
mutagens, and reprotoxicants. Thus, these
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laws are not based on risk assessment for EDs
present in biocides and pesticides, but only
require hazard identification if exposure is
not negligible. This corresponds to so-called
“hazard-based cut-off criteria” (see Figure 1
for the distinction between hazard—a source
of potential health effects—and risk—the
actual impact of a substance in a population,
in terms of disease probability or number of
attributable disease cases). This hazard-based
approach to pesticide and biocide regulation has been opposed by companies that
market pesticides and biocides (CEFIC 2013;
European Commission 2015; European Crop
Protection Association 2014).
In addition, editors of pharmacology
and toxicology journals condemned in an
editorial the proposed European Commission
recommendations on ED regulations, which
they claimed were based on scientifically
unfounded precaution and defied common
sense and well-established risk assessment
principles; the editors called for the consideration of adverse effects and potency (Dietrich
et al. 2013). Their editorial was criticized for
being based on a factually incorrect interpretation of the proposed regulatory framework
and for ignoring the programming role of
the endocrine system during development
Address correspondence to R. Slama, Team of environmental epidemiology, IAB / Inserm-CNRS-Univ
Grenoble-Alpes (U1209) joint research center,
Site Santé, Allée des Alpes, F-38700 La Tronche
(GRENOBLE), France. Telephone: 33-476-54-9402. E-mail: remy.slama@ujf-grenoble.fr
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(Bergman et al. 2013; Gore et al. 2013).
Its authors were also called upon to provide
information about potential conflicts of
interest (Grandjean and Ozonoff 2013).
At a meeting convened by the EU
Commission including signatories of the
Dietrich et al. (2013) editorial and scientists with a strong base in ED research,
a consensus was reached on the definition
of EDs, on the existence of nonmonotonic
dose responses, and on the difficulties of
determining thresholds for EDs (European
Commission 2013).
Despite the obligations to establish scientific criteria to identify EDs by December
2013, as specified by EU laws (European
Parliament 2009a, 2012), no such criteria
have been published to date (April 2016)
by the European Commission. Instead, the
European Commission published a roadmap
listing four options for defining criteria for
identifying EDs and initiated an assessment
of their impact (European Commission 2014)
(Table 1). One of the options included in
the roadmap (option 4) would use potency
as a decision criterion during the process of
hazard identification.
The disregard for the obligations laid
down in EU law led Sweden and several
other EU countries to sue the European
Commission. In December 2015, the
European Court of Justice ruled that the
European Commission acted unlawfully in
failing to develop ED criteria and that an
impact assessment was unnecessary (European
Court of Justice 2015). This judgment heightened the urgency of developing scientificallybased regulatory criteria for identifying EDs.
We elaborate some principles of ED regulation and specifically discuss the scientific
relevance of each option considered by the
European Commission to identify an ED,
reviewing the availability of accepted definitions of EDs, endocrine-active substances,
and the relevance of the concept of potency
for hazard identification. A parallel with
carcinogens is drawn. The relevance of impact
assessment studies to define scientific criteria
is finally discussed.

• Option 2 relies on the WHO definition
to identify EDs (WHO/IPCS 2002). This
option a) identifies EDs as substances
known or presumed to cause endocrinemediated adverse effects in humans or
animal species living in the environment;
b) stipulates that endocrine-mediated
adverse effects should not be a nonspecific secondary consequence of other toxic
effects; c) defines “adverse effects” (as
discussed below); d) excludes substances
for which there is information demonstrating that the effects are not relevant
for humans and for animal species living
in the environment; and finally e) lists the
step-by-step procedure to be followed for
the identification.
• Option 3 relies on the identification of
ED as in Option 2 and further defines
“suspected endocrine disruptors” and
“endocrine active substances” (see below).
• Option 4 relies on the WHO/IPCS definition of ED, and includes “potency” as an
element of hazard characterization. Potency
is not defined, nor is the manner in which it
would be combined with the ED definition.
The European Commission (2014)
indicated that Option 1 (no specification of
criteria) would run counter to the requirements of regulations calling for an operational
definition of EDs. Moreover, the PPPR
and BPR laws mention interim criteria,
and these would likely apply. According to
these interim criteria, all substances classified as carcinogenic category 2 and toxic for
reproduction category 2 shall be considered
as EDs (European Parliament 2009a). These
interim criteria based on the definitions of
carcinogens and reproductive toxicants have
no scientific relevance to the WHO/IPCS
definition of endocrine disruptors (WHO/
IPCS 2002), so Option 1 would not be

scientifically justified. Consequently, we do
not discuss this option further.

Availability of a Definition of EDs
Option 2 of the roadmap defines EDs and
adverse effect. At a workshop convened in
1996 in Weybridge (UK) by the European
Commission, WHO and other institutions, an ED was defined as “an exogenous
substance that causes adverse health effects in
an intact organism, or its progeny, secondary
to changes in endocrine function” (quoted by
EFSA Scientific Committee 2013). Several
definitions were subsequently suggested by
Canadian, Japanese, and other institutions
(reviewed by Kortenkamp et al. 2011),
after which the International Program on
Chemical Safety (IPCS), in collaboration
with experts from Canada, Japan, the United
States, and the EU, defined an ED as “an
exogenous substance or mixture that alters
the function(s) of the endocrine system
and consequently causes adverse effects in
an intact organism, or its progeny, or (sub)
populations” (WHO/IPCS 2002). The main
differences from the Weybridge definition are
the consideration of mixtures and of effects in
populations or subpopulations.
The definition issued from the workshop
convened by the U.S. Environmental
Protection Agency (EPA) in 1995 in Raleigh,
North Carolina (Kavlock et al. 1996), which
is still referred to by the U.S. EPA (2015),
differs from the WHO/IPCS definition
by lack of reference to adverse effects. As
discussed below, substances acting on the
endocrine system without evidence of an
adverse health effect would be defined as
endocrine-active substances under Option 3.
For other categories of health hazards,
specific adverse health effects are often
referred to, as is the case for carcinogens or

Discussion
Proposed Options Regarding
Criteria for EDs in Europe
The general intention of defining ED criteria
is “to ensure a high level of protection to
human health and the environment and to
strengthen the functioning of the internal
market” (European Commission 2014).
The four options proposed (European
Commission 2014) are detailed in Table 1
and summarized below:
• Option 1 consists of no policy change and
no specification of criteria.
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Figure 1. Hazard-based versus risk-based management of hazards. The step of risk characterization is
sometimes (ambiguously) termed hazard characterization.
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reprotoxins, whereas for mutagens there
is only a reference to a mode of action. The
WHO/IPCS definition of EDs refers to both
a mode of action and an adverse effect at the
scale of organs, organisms, or populations.
Consequently, conclusions about the nature
of an ED require the integration of biochemical, toxicological, and ecotoxicological/
human data.
EFSA (European Food Safety Authority)
recommended that the WHO/IPCS definition be “adopted as a basis for the criteria for
the identification of EDs” (EFSA Scientific
Committee 2013). The European Commission
roadmap acknowledges that “there is general
consensus on the WHO/IPCS (2002) definition of an ED” (European Commission 2014).
The ED definition mentions “adverse
effects.” Adverse effects were defined as a
“change in the morphology, physiology,
growth, development, reproduction or lifespan

of an organism, system or (sub)population
that results in an impairment of functional
capacity, an impairment of the capacity to
compensate for additional stress or an increase
in susceptibility to other influences” (WHO/
IPCS 2009). The EC roadmap explicitly refers
to this definition. This definition covers health
effects at the individual level such as occurrence of diabetes or obesity, IQ loss, as well
as congenital malformations, or changes not
visible at the individual but only at the population level, such as alteration of the sex ratio.
It excludes, among others, transient changes
in hormone levels that would not induce
health effects in the short or long term. To our
knowledge, this definition has not been questioned. The expression of “(sub)population”
in WHO/IPCS definition refers to effects that
may concern the population as a whole or
a specific subgroup (e.g., based on sex, age,
genetic susceptibility).

Suspected EDs and Endocrine
Active Substances (Option 3)

In addition to defining an ED as in Option 2,
Option 3 proposes two additional categories, suspected endocrine disruptors and
endocrine-active substances, that express the
strength of evidence for a given compound.
“Suspected endocrine disruptors” are
defined in the roadmap as “Substances where
there is some evidence for endocrine-mediated
adverse effects from humans, animal species
living in the environment or from experimental studies, but where the evidence is not
sufficiently strong to place the substance in
Category I” (European Commission 2014).
This definition is close to the WHO/IPCS
definition of a “possible endocrine disruptor”
(“an exogenous substance or mixture that
possesses properties that might be expected
to lead to endocrine disruption in an intact
organism, or its progeny, or (sub)populations”)

Table 1. Four options to identify endocrine-disrupting substances in the EC 2014 roadmap (European Commission 2014).
Option
Details
1
No criteria are specified. The interim criteria set in the BPR and PPPR continue to apply.

2

3

4

WHO/IPCS definition (WHO/IPCS 2002) to identify ED (hazard identification). ED are identified as:
a) Substances that are i) known or presumed to have caused endocrine-mediated adverse effects in
humans or population-relevant endocrine-mediated adverse effects in animal species living in the
environment or ii) where there is evidence from experimental studies (in vivo), possibly supported with
other information (e.g., QSAR, analogue, and category approaches) to provide a strong presumption
that the substance has the capacity to cause endocrine-mediated adverse effects in humans or
population-relevant endocrine-mediated adverse effects on animal species living in the environment;
b) The experimental studies used to determine if a substance is an endocrine disruptor shall provide clear
evidence of endocrine-mediated adverse effects in the absence of other toxic effects, or, if occurring
together with other toxic effects, the endocrine-mediated adverse effects should not be a nonspecific
secondary consequence of other toxic effects;
c) An adverse effect is a change in the morphology, physiology, growth, development, reproduction, or life
span of an organism, system, or (sub)population that results in an impairment of functional capacity,
an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to
other influences, as stated by WHO/IPCS (2009);
d) where there is (e.g., mechanistic) information demonstrating that the effects are clearly not relevant
for humans and not relevant at population level to animal species living in the environment, then the
substance should not be considered an endocrine disruptor;
e) The identification shall follow a step-by-step procedure as follows: i) gather all available data; ii) assess
the data quality, reliability, reproducibility, and consistency; iii) consider adversity and mode of action
together in a weight-of-evidence approach based on expert judgment; iv) evaluate whether endocrine
disruption is attributable to a specific endocrine-mediated mode of action and not to a nonspecific
secondary consequence of other toxic effects; v) evaluate human and wildlife relevance; vi) final (eco)
toxicological evaluation indicating, where possible, whether the adverse effect is in relation to human
health or environment (vertebrates and/or invertebrate populations), and where possible which are the
axes or mechanisms concerned (e.g., estrogenic, androgenic, thyroid, and/or steroidogenic axes).
WHO/IPCS (2002) definition to identify ED (hazard identification) as in Option 2. Introduction of additional
categories based on the different strength of evidence for fulfilling the WHO/IPCS definition:
Category I: “endocrine disruptors” (as defined in 2a–2d).
Category II: “suspected endocrine disruptors,” defined as substances where there is some evidence
for endocrine-mediated adverse effects from humans, animal species living in the environment, or
experimental studies, but where the evidence is not sufficiently strong to place the substance in Category I.
If, for example, limitations in the studies make the quality of evidence less convincing, Category II could be
more appropriate. Points 2b, 2c (definition of adverse effect), and 2d above remain valid for Category II.
Category III: “endocrine-active substances,” defined as substances for which there is some in vitro
or in vivo evidence indicating a potential for endocrine disruption–mediated adverse effects in intact
organisms and where the evidence is not sufficiently convincing to place the substance in Category I or II.
The allocation to categories shall follow a step-by-step procedure (identical to that listed in 2e above).
WHO/IPCS definition (WHO/IPCS 2002) to identify ED (hazard identification) and inclusion of potency as
element of hazard characterization.

Comments
Would run counter to the PPPR and BPR, which require
scientific criteria to be defined. Would lead to the interim
criteria [which are not coherent with the WHO/IPCS
(2002) definition of EDs] to be used.

The definition of “endocrine-active substances”
(Category III) does not follow the definition provided by
EFSA, which refers to substances that can interfere or
react with the endocrine system (without evidence of
adverse effect).

Potency is not defined. Option 4 introduces elements of
risk assessment. No step-by-step procedure provided as
in 2 and 3.

Abbreviations: BPR, Biocide Products Regulation (EU); PPPR, Plant Protection Products Regulation (EU); QSAR, quantitative structure–activity relationship.

Environmental Health Perspectives •

volume

124 | number 10 | October 2016

1499

Slama et al.

(WHO/IPCS 2002). “Endocrine-active
substances” are defined in the European
Commission roadmap as “Substances for which
there is some … potential for endocrine disruption mediated adverse effects in intact organisms and where the evidence is not sufficiently
convincing to place the substance in category I
[ED] or II [suspected ED]” (European
Commission 2014). We believe that the terminology of “endocrine-active substance” does
not convey this lower level of evidence (a hierarchy such as ED [category I], presumed ED
and suspected ED, similar to that of carcinogens shown in Table 2, would better fit this
purpose). In contrast, an “endocrine-active
substance” is defined by EFSA as “any chemical
that can interact directly or indirectly with the
endocrine system, and subsequently result in
an effect on the endocrine system, target organs
and tissues” (EFSA Scientific Committee
2013). The term is used to cover “all substances
that in some way interfere with the endocrine
system, but need not necessarily induce adverse
effects.” This definition transmits the notion
that there is evidence regarding the mode of
action of the substance (interference with the
endocrine system), but not regarding the induction of adverse effects, which is in line with the
terminology of endocrine-active substances.
Therefore, we suggest using the EFSA definition for endocrine-active substances instead of
the EC roadmap definition.

Introduction of Potency as a
Criterion for Hazard Identification
(Option 4)
Option 4 of the roadmap is based on the
WHO/IPCS definition of an ED, with
potency as an added criterion. This option
echoes approaches developed by the United
Kingdom and German authorities with the
explicit intention of limiting the number of
substances that would fall under the hazardbased cut-off criteria of the PPPR and BPR
(discussed by Kortenkamp et al. 2011). A

publication from the German federal institute
for risk assessment also suggested to consider
potency to identify EDs (Marx-Stoelting
et al. 2015).
Potency is not well defined; it is not in
the glossary of terms of the environmental
health criteria published by the International
Program on Chemical Safety (IPCS 2009).
The term is presented in a publication sponsored by ECETOC—the European Centre for
Ecotoxicology and Toxicology of Chemicals,
a nonprofit association of companies with
interests in the manufacture and use of
chemicals—as being “primarily based on the
dose causing a specific toxic effect” without
being clearly defined (Hennes et al. 2014). A
publication from the German federal institute for risk assessment indicates that “Potency
relates to the dose levels at which certain
effects occur” (Marx-Stoelting et al. 2015).
The International Union of Pharmacology
defines potency as “an expression of the activity
of a drug, in terms of the concentration or
amount needed to produce a defined effect; an
imprecise term that should always be further
defined (see EC50, IC50, etc.),” where EC50
is further defined as “The molar concentration of an agonist that produces 50% of the
maximal possible effect of that agonist. Other
percentage values (EC20, EC40, etc.) can be
specified” (Neubig et al. 2003).
Hence, in pharmacology, potency is
related to the dose–response function: A
substance that at a certain dose causes 50%
of its possible maximal effect magnitude
(e.g., rate of animals with a specific disease)
is considered more potent than another
substance for which the same effect magnitude is attained at a larger dose. As already
mentioned (Neubig et al. 2003), sometimes
doses other than those leading to 50% of
a given effect are used, such as 10% of a
given effect, without apparent scientific
justification of how these cut-off values are
chosen. Thus, potency is simply a point of

the dose–response function, corresponding
to the dose at which this dose–response
function intersects an arbitrary response level
(Figure 2A).
The step-by-step procedure of the EC
roadmap (Options 2 and 3) mentions that
it is necessary to evaluate whether endocrine disruption is attributable to a specific
endocrine-mediated mode of action and not
to a nonspecific secondary consequence of
other toxic effects (European Commission
2014). Consequently, effects that would
occur at very high doses at which general
toxicity is observed would not be enough to
qualify the compound as an ED, without the
need to explicitly introduce concepts related
to the dose at which effects occur.
The introduction of potency as a criterion in hazard identification would lead to
several difficulties. First, this concept is not
suited for compounds for which nonmonotonic dose–response functions are possible,
as is the case for EDs (Vandenberg et al.
2012). Second, the introduction of potency
as a decision criterion may force the establishment of dichotomous regulatory cut-off
values that are entirely arbitrary and not
science-based, such that a compound with
a potency of 10 mg/kg/day might be classified as an ED, while a compound with a
potency of 11 mg/kg/day (hence causing the
same effect at an exposure of 11 instead of
10 mg/kg/day) would not be classified as an
ED. Third, potency comparisons are influenced by the effect magnitude that is chosen to
define the doses to be compared (i.e., whether
one considers a 10% or a 50% increase; see
Figure 2A) and by the health end point considered to define potency. Overall, potency is not
a relevant concept for hazard identification.
Even in the context of risk management,
potency alone is of little use. Indeed, dose–
response functions, from which potency is
defined, are not meaningful alone and need
to be interpreted in relation to exposure,

Figure 2. Illustration of issues with the potency concept, with hypothetical dose–response functions and distributions of exposure. (A) Situation of dose–response
functions that cross: If potency is defined as the dose ED50 leading to 50% of a given response, then chemical with the dose–response function a is considered
more potent than chemical with exposure–response function b; if potency is defined as the dose leading to 10% of the response (ED10), then chemical with dose–
response function a is less potent than chemical with dose–response function b. (B) Shallow dose–response function (and low potency) with a large proportion
of highly exposed subjects, hence entailing a possibly high risk. (C) Steep dose–response function (and high potency) with a low proportion of highly exposed
subjects, hence entailing a possibly similar or lower risk. Blue bars in B and C represent the distribution of exposure in the population.
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which allows estimation of the level of risk for
a given population (Figure 1). Low potency
compounds with shallow dose–response functions and very frequent exposures (Figure 2B)
may present greater risks at the population
level than more potent chemicals with steep
dose–response functions but less frequent
exposure (Figure 2C). Well-established
examples illustrating that the dose response
(or potency) cannot be considered alone to
predict risk include airborne fine particulate
matter (≤ 2.5 μm; PM2.5) (WHO 2014) and
low exposures during critical windows of
vulnerability like fetal development, such as
those demonstrated for effects of PCBs on
intellectual quotient (Jacobson and Jacobson
1996; Schantz et al. 2003). Accordingly, the
EFSA scientific committee stated “that, to
assess whether or not a (predefined) level of
concern is reached for an ED, potency should
not be used alone but should take account of
actual or predicted exposure” (EFSA Scientific
Committee 2013). Indeed, potency replaces
dose–response curves by a single point of the
curve, which results in a strong loss of information. If a risk-based and not hazard-based
management is chosen, the relevant approach
is to take into account the variations of the
dose–response function over the whole range
of exposures and combine it with actual
exposures, for all relevant health outcomes, in
other words to explicitly perform a risk assessment study—but this goes beyond the steps
required for hazard identification.
In the context of the PPPR, where some
substances are to be regulated mostly on
the basis of their hazard (at least if exposure
is not negligible) and not their risk, considering dose–response functions (or potency) at
the step of hazard identification would lead
to reintroducing a logic of risk assessment.
The discussion of whether or not the hazardbased logic of the PPPR and BPR for EDs
should be modified into a risk-based regulation is a matter of policy. If deemed relevant
by regulators, risk assessment should not be
reintroduced partially (by considering only a
component of risk assessment), nor “by the
back door,” indirectly, by requiring consideration of a criterion related to risk assessment such as potency. Rather, if necessary,
this should be done explicitly, by modifying
the legislation.

are defined as “a substance or a mixture of
substances which induce cancer or increase
its incidence. Substances which have
induced benign and malignant tumors in
well-performed experimental studies on
animals are considered also to be presumed
or suspected human carcinogens unless there
is strong evidence that the mechanism of
tumor formation is not relevant for humans”
(European Parliament 2008). For carcinogens, the EU defines three categories for
carcinogenic substances (Ia, Ib, and II, the
last corresponding to suspected carcinogens,
Table 2). The classification of a substance in
any category is based on a scientific assessment
of the hazard (hazard identification) and does
not take into consideration other components
of the risk assessment scheme (Figure 1) such
as “potency.” Opting for options 2 or 4 would
separate EDs from other hazards of equivalent
concerns because the number of hazard categories would differ (in the case of Option 2,
for which a substance is either identified as an
ED or not, not alerting industry, consumers
or policy makers to suspected EDs) or because
potency would be considered (Option 4).
This would run counter to the policy choice
of the legislation to consider EDs as being of
equivalent concern to carcinogens, mutagens,
and reprotoxicants. Overall, the example of
carcinogens shows that criteria defining a
serious hazard need not be complex, nor need
to resort to potency and risk-related concepts.

Parallel with Hazard Identification
in the Field of Carcinogens

In the right-hand column, we have added the 3 levels for EDs proposed in Option 3 of the European Commission (2014)
roadmap.
aA carcinogen is defined as a substance or a mixture of substances which induce cancer or increase its incidence.
Substances that have induced benign and malignant tumors in well-performed experimental studies on animals are
considered also to be presumed or suspected human carcinogens unless there is strong evidence that the mechanism
of tumor formation is not relevant for humans (European Parliament 2008). bA substance is classified in Category I
for carcinogenicity on the basis of epidemiological and/or animal data. A substance may be further distinguished as
Category IA, known to have carcinogenic potential for humans, classification largely based on human evidence, or
Category IB, presumed to have carcinogenic potential for humans, classification largely based on animal evidence.
cAccording to the EU regulation, the placing of a substance in Category II (suspected human carcinogens) is done on
the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place
the substance in Category IA or IB, based on strength of evidence together with additional considerations. Such
evidence may be derived either from limited evidence of carcinogenicity in human studies or from limited evidence of
carcinogenicity in animal studies.

Another key argument against adopting
criteria considering potency is consistency
with the identification of other hazards
of similar concern, such as carcinogens or
reproductive toxicants. Several other types
of chemical hazards are explicitly referred
to in the EU regulation, including carcinogens, mutagens, reprotoxins. Carcinogens
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Impact Assessment Studies Are
Not Designed to Help Defining
Hazards
The European Commission is carrying out
an impact assessment as a preliminary step
before deciding among the four options.
Impact assessment studies provide an assessment of the potential economic, social and

environmental impacts of alternative policy
options. They would make sense if policy
options were currently examined (e.g.,
between hazard-based regulation of pesticides or risk-based regulation), or after the
implementation of a policy to judge its results.
Here the relevant regulations (PPPR, BPR,
REACH laws) have already been enacted but
not applied as far as EDs are concerned.
Scientific criteria should rely on a scientific foundation. It is not the evaluation of
the impact of a family of compounds that
should guide their scientific definition; rather,
the adoption of a scientific definition conditions any impact evaluation. Continuing the
previous parallel with other health hazards,
carcinogens were defined before obtaining
a clear picture of the number of existing
carcinogens, and independently of their
impact. Similarly, it would not be necessary
to perform an impact assessment study before
defining X-rays or explosives.
Studies of the impact of some EDs on
disease burden and cost in Europe have
already been published (Trasande et al.
2015). The economic cost associated with
exposure to non-banned EDs in the EU was
estimated to be 157 billion euros per year
(Trasande et al. 2015).
If option A leads to the identification of
10 substances that are EDs while option B
identifies 50 further substances, will option B
be preferred to limit the health impact of EDs
or will option A be chosen to limit constraints
on the industrial sector? Economic and health
impacts are subject to quick changes as a
function of exposure levels, development of
substitutes or alternative industrial processes,
and existence of companies with relevant
substitutes. Will the impact assessment be
updated to take these changes into account,
and the criteria modified accordingly?

Table 2. Categories of carcinogenic substances, as defined by the EU CLP regulation (EC, No. 1272/2008
on classification, labeling and packaging of substances and mixtures).
Endocrine-disrupting chemicals
(Option 3 of the EC roadmap)

Carcinogensa
Hazard class
Category Ia
Category Ib
Category II

Substances known to have carcinogenic
potential for humansb
Substances presumed to have carcinogenic
potential for humansb
Suspected human carcinogensc

124 | number 10 | October 2016

Hazard class
I
II

Substances known or presumed
to be an endocrine disruptor
Suspected endocrine disruptors

III

Endocrine-active substances
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In its ruling against the European
Commission, the European court of justice
stated that “the definition of scientific criteria
to identify properties disrupting the endocrine system can only be done in an objective
manner based on scientific data relative to the
endocrine system, independently from any
other consideration, and in particular from any
economic consideration” (European Court of
Justice 2015). Making a scientific definition
dependent on the results of an assessment of
its impact would be a dangerous precedent for
public health and science in general.

Conclusion
The laws passed by the European parliament during the last decade constitute an
innovative approach to limit health risks
posed by EDs.
We have presented and discussed each
option proposed by the European Commission
to identify EDs (European Commission
2014), and provided specific recommendations
(Table 3). Only Options 2 and 3 comply with
science. There is scientific consensus on the
relevance of the WHO/IPCS definition of an
ED (WHO/IPCS 2002). Option 4 modifies
this definition by introducing the notion of
potency, which is absent from the WHO/
IPCS definition and from the criteria identifying carcinogens, which are hazards of equivalent concern to EDs. We believe that, because
of the parallel with definitions of carcinogenic
hazards (which have different categories based
on evidence levels) and because it calls for the
identification of suspected EDs, Option 3 is
more relevant. This will provide a simple classification conveying the weight of the scientific evidence regarding the likelihood for the
compound to be an ED: endocrine disruptors
(including substances known or presumed to
be EDs), suspected endocrine disruptors, and
endocrine-active substances (Table 2).
We recognize that scientific uncertainty
remains with regard to the finer detail of mechanisms, the exact extent of health and environmental effects of EDs, and their impact at the

population level. There are also great uncertainties as to the number of substances likely to be
identified as EDs. However, as demonstrated
by the 40 years of work by the International
Agency for Research on Cancer to identify
carcinogens (Pearce et al. 2015), the availability
of a clear definition of the hazard considered is
a necessary first step. Once defining criteria are
available, one can develop appropriate testing
methods, identify substances, and manage risk.
Some of the test methods that will be required
for regulatory purposes need to be developed
and agreed upon.
There is no scientific or public health
justification for the delay in the adoption of
scientific criteria for EDs.
As scientists, we believe that impact assessment studies should not be used to define
scientific criteria, nor be used as an argument
for postponing the publication of a scientific
definition. We are concerned that an impact
assessment study could be used to bend
science toward an outcome defined by aspects
external to science. We are convinced that
the (vague) notion of potency has no place
in a hazard identification context. We are
concerned that scientific definitions are being
distorted in order to modify the spirit of a
law that requires hazard-based management
of EDs present in pesticides if exposure is not
negligible, and not a risk-based management,
thereby muddling science and policy. We
believe that scientific criteria identifying EDs
should follow the logic of the EU criteria for
other serious hazards such as carcinogens and
reproductive toxicants. We regret that several
years have been spent trying to issue scientific criteria defining a hazard that actually has
been defined years earlier by a state-of-thescience report from WHO. We fear that the
most plausible explanation for this delay is not
a lack of scientific consensus, but rather that
postponing the publication of the scientific
criteria is a way to postpone the full application of the 2009 pesticide regulation and 2012
biocide European regulation. This postponement is all the more worrying because these

Table 3. Recommendations.
Recommendation
1. Refer to the WHO/IPCS (2002) definition of EDs,
potential (suspected) ED, and adverse effects; and to
the EFSA definition of endocrine active substances.
2. Identify hazards without referring to potency.

3. Consider hazard identification and risk characterization
as separate issues. Do not use scientific criteria to
move from a hazard-based to a risk-based regulation for
specific substances.
4. Establish scientific ED criteria regardless of an impact
assessment study.
5. Incorporate the level of evidence in characterization of
EDs (Option 3).
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Rationale
Follow scientific consensus.
Potency is poorly defined and end point dependent,
is not used to define other hazards of equivalent
concern such as carcinogens, and belongs to risk
assessment, not hazard identification.
Any change in the spirit of the law should be done
explicitly in the law, not via a delegate act.
Impact assessment studies are not meant to provide
scientific definitions.
Proven to be relevant for carcinogens and other
hazardous substances of equivalent concern to EDs.

volume

scientific criteria are but one of the first steps
toward identifying EDs and providing more
efficient protection of public health in the
European Union.
Note added in proof: After acceptance of this
manuscript, on 16 June 2016, the European
Commission published proposals to define EDs in
the context of the pesticides and biocides regulations (European Commission 2016). The proposal
suggested abandoning the hazard-based logic of
management of pesticides containing EDs. See
Kortenkamp et al. (2016) for a comment.
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